Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure

Table 1

Baseline and procedural characteristic comparisons of the study population.

Baseline characteristics	Rivaroxaban ()	Dabigatran ()	value
Age (y)			0.764
Gender (male, %)	40 (48.8)	23 (60.5)	0.231
Stroke and bleeding risk factors
CHF	3 (3.7)	0 (0.0)	0.551
Hypertension	16 (19.5)	8 (21.1)	0.844
y	20 (24.4)	11 (28.9)	0.596
Diabetes mellitus	52 (63.4)	24 (63.2)	0.978
Stroke/TIA	56 (68.3)	23 (60.5)	0.404
Vascular disease	33 (40.2)	21 (55.3)	0.124
Age (65-74 y)	38 (46.3)	18 (47.4)	0.916
Sex category (female gender)	40 (48.8)	17 (44.7)	0.680
Abnormal renal function	19 (23.2)	6 (15.8)	0.354
Abnormal liver function	6 (7.3)	3 (7.9)	1.000
Bleeding history	7 (8.5)	4 (10.5)	0.741
Drug interactions	42 (51.2)	21 (55.3)	0.680
Alcohol	8 (9.8)	2 (5.3)	0.501
Coronary heart disease	13 (15.9)	8 (21.1)	0.486
WATCHMAN size (dm, cm)			0.669
LVEF, %			0.564
CHA2DS2-VASc score
3-4	44 (53.7)	20 (52.6)	0.916
≥5	10 (12.2)	2 (5.3)	0.335
HAS-BLED score
0-2	20 (24.4)	11 (28.9)	0.596
≥3	62 (75.6)	27 (71.1)	0.596

Values are , (%). value was calculated with two-way ANOVA analysis and represented with interaction, was considered significant. CHF: congestive heart failure; TIA: transient ischemic attack; LVEF; left ventricular ejection fraction; CHA₂DS₂-VAS_c risk calculated with risk factors congestive heart failure, hypertension, years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, and sex category; HAS-BLED risk score calculated with hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs, or alcohol.